Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

摘要

In this multicenter, phase II, single-arm study, 52 patients with recurrent or metastatic HER2-positive (+) breast cancer received first-line eribulin with trastuzumab. The objective response rate (ORR) was 71.2% (n = 37) with a median time to first response (TTR) of 1.3 months; duration of response (DOR) and progression-free survival (PFS) were 11.1 and 11.6 months, respectively. Eribulin/trastuzumab combination resulted in a substantial tumor response with an acceptable safety profile.